Nanoparticles-in-Microsphere Oral Delivery Systems (NiMOS) for nucleic acid therapy in the gastrointestinal tract

Mucosal Delivery of Biopharmaceuticals: Biology, Challenges and Strategies

Volumn , Issue , 2013, Pages 283-312

  Jain, Shardool ^a   Amiji, Mansoor ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Gene therapy; IL 10 plasmid DNA; Inflammatory bowel disease; Nanoparticles in microsphere oral system (NiMOS); RNA interference; TNF specific siRNA

Indexed keywords

EID: 84930026946     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-9524-6_11     Document Type: Chapter

References (57)

1. Kawakami S, Higuchi Y, Hashida M. Nonviral approaches for targeted delivery of plasmid DNA and oligonucleotide. J Pharma Sci. 2008;97(2):726-45.
2. Goverdhana S, Puntel M, XiongW, Zirger JM, Barcia C, Curtin JF, Soffer EB, Mondkar S, King GD, Hu J, Sciascia SA, Candolfi M, Greengold DS, Lowenstein PR, Castro MG. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther. 2005;12(2):189-211.
3. Bhavsar MD, Amiji MM. Polymeric nano-And microparticle technologies for oral gene delivery. Expert Opin Drug Deliv. 2007;4(3):197-213.
4. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001;7(1):33-40.
5. Mahapatro A, Singh DK. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnol. 2011;9:55.
6. Dass CR, Choong PF. Chitosan-mediated orally delivered nucleic acids: a gutful of gene therapy. J Drug Target. 2008;16(4):257-61.
7. Petkar KC, Chavhan SS, Agatonovik-Kustrin S, Sawant KK. Nanostructured materials in drug and gene delivery: a review of the state of the art. Crit Rev Ther Drug. 2011;28(2):101-64.
8. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427-34.
9. Wu F, Dassopoulos T, Cope L, Maitra A, Brant SR, Harris ML, Bayless TM, Parmigiani G, Chakravarti S. Genome-wide gene expression differences in Crohn's disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive pathogenesis. Inflamm Bowel Dis. 2007;13(7):807-21.
10. Perrier C, Rutgeerts P. Cytokine blockade in inflammatory bowel diseases. Immunotherapy. 2011;3(11):1341-52.
11. Talley NJ, AbreuMT, Achkar JP, Bernstein CN, DubinskyMC, Hanauer SB, KaneSV, Sandborn WJ, Ullman TA, Moayyedi P. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106(Suppl 1):S2-25; quiz S26.
12. Nakase H, Okazaki K, Tabata Y, Chiba T. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease. J Gastroenterol. 2003;38(Suppl 15):59-62.
13. Kaigler D, Cirelli JA, Giannobile WV. Growth factor delivery for oral and periodontal tissue engineering. Expert Opin Drug Deliv. 2006;3(5):647-62.
14. Sood S, Gupta S, Mahendra A. Gene therapy with growth factors for periodontal tissue engineering-A review. Med Oral Patol Oral Cir Bucal. 2012;17(2):e301-10.
15. Zhang Y, Wang Y, Shi B, Cheng X. A platelet-derived growth factor releasing chitosan/coral composite scaffold for periodontal tissue engineering. Biomaterials. 2007;28(8):1515-22.
16. Peng L, Cheng X, Zhuo R, Lan J, WangY, Shi B, Li S. Novel gene-Activated matrix with embedded chitosan/plasmid DNA nanoparticles encoding PDGF for periodontal tissue engineering. J Biomed Mater Res A. 2009;90(2):564-76.
17. Elangovan S, Jain S, Tsai PC, Margolis HC, Amiji M. Nano-sized calcium phosphate particles for periodontal gene therapy. J Periodontol. 2013;84(1):117-25.
18. Bowman K, Sarkar R, Raut S, LeongKW. Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles. J Control Release. 2008;132(3):252-9.
19. Azad N, Rojanasakul Y. Vaccine delivery-current trends and future. Curr Drug Deliv. 2006;3(2):137-46.
20. Chadwick S, Kriegel C, Amiji M. Delivery strategies to enhance mucosal vaccination. Expert Opin Biol Ther. 2009;9(4):427-40.
21. Srivastava IK, Singh M. DNA vaccines: focus on increasing potency and efficacy. Int J Pharm Med. 2005;19:15-28.
22. Singh M, O'Hagan DT. Recent advances in vaccine adjuvants. Pharm Res. 2002;19(6):715-28.
23. Singh M, Chakrapani A, O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines. 2007;6(5):797-808.
24. Shahiwala A, Vyas TK, Amiji MM. Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat Drug Deliv Formul. 2007;1(1):1-9.
25. Clark MA, Jepson MA, Hirst BH. Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev. 2001;50(1-2):81-106.
26. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature. 2004;431(7006):343-9.
27. Mello CC, Conte Jr. D.Revealing the world of RNA interference. Nature. 2004;431(7006): 338-42.
28. FilipowiczW, Jaskiewicz L, Kolb FA, Pillai RS. Post-Transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol. 2005;15(3):331-41.
29. Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther. 2006;13(4):644-70.
30. Amarzguioui M, Prydz H.An algorithm for selection of functional siRNA sequences. Biochem Biophys Res Commun. 2004;316(4):1050-8.
31. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol. 2004;22(3):326-30.
32. Peacock H, Kannan A, Beal PA, Burrows CJ. Chemical modification of siRNA bases to probe and enhance RNA interference. J Org Chem. 2011;76(18):7295-300.
33. Bramsen JB, Kjems J. Chemical modification of small interfering RNA. Methods Mol Biol. 2011;721:77-103.
34. Wilson DS, Dalmasso G, Wang L, SitaramanSV, Merlin D, Murthy N. Orally delivered thioketal nanoparticles loaded with TNF-Alpha-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater. 2010;9(11):923-8.
35. Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, Ostroff GR, Czech MP. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature. 2009;458(7242):1180-4.
36. BenoitMA, Baras B, Gillard J. Preparation and characterization of protein-loaded poly(epsiloncaprolactone) microparticles for oral vaccine delivery. Int J Pharm. 1999;184(1):73-84.
37. Florence AT the oral absorption of micro-And nanoparticulates: neither exceptional nor unusual. Pharm Res. 1997;14(3):259-66.
38. Bhavsar MD, Tiwari SB, Amiji MM. Formulation optimization for the nanoparticlesin-microsphere hybrid oral delivery system using factorial design. J Control Release. 2006;110(2):422-30.
39. Kaul G, Amiji M. Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharm Res. 2002;19(7):1061-7.
40. Kaul G, Amiji M. Tumor-Targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: in vitro and in vivo studies. Pharm Res. 2005;22(6): 951-61.
41. BhavsarMD, AmijiMM.Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J Control Release. 2007;119(3):339-48.
42. Kriegel C, Amiji M. Oral TNF-Alpha gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J Control Release. 2011;150(1):77-86.
43. Bhavsar MD, Amiji MM. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther. 2008;15(17):1200-9.
44. Krigel C, Amiji M. Dual TNF-α/Cyclin D1 gene silencing with an oral polymeric microparticle system as a novel strategy for the treatment of inflammatory bowel disease. Clin Transl Gastroenterol. 2011;2(e2):1-12.
45. Bozkir A, Hayta G. Preparation and evaluation of multiple emulsions water-in-oil-in-water (w/o/w) as delivery system for influenza virus antigens. J Drug Target. 2004;12(3):157-64.
46. Dupuis M, Murphy TJ, Higgins D, Ugozzoli M, van Nest G, Ott G, McDonald DM. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol. 1998;186(1): 18-27.
47. Shahiwala A, Amiji MM. Enhanced mucosal and systemic immune response with squalane oilcontaining multiple emulsions upon intranasal and oral administration in mice. J Drug Target. 2008;16(4):302-10.
48. Kalariya M, Ganta S, Amiji M. Multi-compartmental vaccine delivery system for enhanced immune response to gp100 peptide antigen in melanoma immunotherapy. Pharm Res. 2012;29(12):3393-403.
49. KawakamiY, Dang N, Wang X, Tupesis J, Robbins PF, Wang RF, Wunderlich JR, Yannelli JR, Rosenberg SA. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother. 2000;23(1):17-27.
50. Sikora AG, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier SW, Schluns KS, Frasca L, Lou Y, Liu C, Andersson HA, Hwu P, Overwijk WW. IFN-Alpha enhances peptide vaccineinduced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol. 2009;182(12):7398-407.
51. Attarwala H, Amiji M. Multi-compartmental nanoparticles-in-emulsion formulation for macrophage-specific anti-inflammatory gene delivery. Pharm Res. 2012;29(6):1637-49.
52. Fujiwara N, Kobayashi K. Macrophages in inflammation. Curr Drug Targets-Inflamm Allergy. 2005;5:281-6.
53. Ross JA, Auger MJ the biology of the macrophage. In: Burke B, Lewis CE, editors the Macrophage, 2 edn. NewYork: Oxford University Press; 2002. pp. 16-23.
54. Gupta S, Dube A, Vyas SP. Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis. J Drug Target. 2007;15(6):437-44.
55. Herre J, Gordon S, Brown GD. Dectin-1 and its role in the recognition of beta-glucans by macrophages. Mol Immunol. 2004;40(12):869-76.
56. Jain SK, GuptaY, Jain A, Saxena AR, Khare P. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomedicine. 2008;4(1):41-8.
57. SchaferV, von Briesen H, Andreesen R, SteffanAM, Royer C, Troster S, Kreuter J, Rubsamen-Waigmann H. Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting. Pharm Res. 1992;9(4):541-6.